BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 26593949)

  • 1. Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer.
    Ojo D; Lin X; Wong N; Gu Y; Tang D
    Cancers (Basel); 2015 Nov; 7(4):2290-308. PubMed ID: 26593949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
    Chandrasekar T; Yang JC; Gao AC; Evans CP
    Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroid hormone synthetic pathways in prostate cancer.
    Mostaghel EA
    Transl Androl Urol; 2013 Sep; 2(3):212-227. PubMed ID: 25379460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.
    Fujimoto N
    J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
    Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
    Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation.
    Simon I; Perales S; Casado-Medina L; Rodríguez-Martínez A; Garrido-Navas MDC; Puche-Sanz I; Diaz-Mochon JJ; Alaminos C; Lupiañez P; Lorente JA; Serrano MJ; Real PJ
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33807106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abiraterone in the treatment of metastatic castration-resistant prostate cancer.
    Mostaghel EA
    Cancer Manag Res; 2014; 6():39-51. PubMed ID: 24501545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor.
    Tilki D; Schaeffer EM; Evans CP
    Eur Urol Focus; 2016 Dec; 2(5):499-505. PubMed ID: 28723515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Molecular Evolution of Castration-resistant Prostate Cancer.
    Ceder Y; Bjartell A; Culig Z; Rubin MA; Tomlins S; Visakorpi T
    Eur Urol Focus; 2016 Dec; 2(5):506-513. PubMed ID: 28723516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer.
    Rice MA; Malhotra SV; Stoyanova T
    Front Oncol; 2019; 9():801. PubMed ID: 31555580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
    Coutinho I; Day TK; Tilley WD; Selth LA
    Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
    Fizazi K; Smith MR; Tombal B
    Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Androgen Receptor in Prostate Cancer: A Review.
    Fujita K; Nonomura N
    World J Mens Health; 2019 Sep; 37(3):288-295. PubMed ID: 30209899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling.
    Zaslavsky AB; Gloeckner-Kalousek A; Adams M; Putluri N; Venghatakrishnan H; Li H; Morgan TM; Feng FY; Tewari M; Sreekumar A; Palapattu GS
    Neoplasia; 2015 Jun; 17(6):490-6. PubMed ID: 26152357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy.
    Terrisse S; Zitvogel L; Kroemer G
    Microb Cell; 2022 Dec; 9(12):202-206. PubMed ID: 36483309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulated androgen synthesis and anti-androgen resistance in advanced prostate cancer.
    Armstrong CM; Gao AC
    Am J Clin Exp Urol; 2021; 9(4):292-300. PubMed ID: 34541028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer via Its Promotion of Intratumoral Androgen Biosynthesis.
    Xiao L; Wang Y; Xu K; Hu H; Xu Z; Wu D; Wang Z; You W; Ng CF; Yu S; Chan FL
    Cancer Res; 2018 May; 78(9):2205-2218. PubMed ID: 29438990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
    Linder A; Larsson K; Welén K; Damber JE
    Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.